Scholars Central

Conference abstractPublished 16 Jun 2016

Designed bispecific molecules selectively inhibiting both jak2 and hdac at low nanomolar concentrations

Authors: Brian W Dymock

University of Singapore, Singapore

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Inhibitors of Janus Kinases (JAKs) for the treatment of myelofibrosis as well as other cancer and non-cancer indications are finding increasing utility. Following the discovery in 2005 of an activating mutation in JAK2, several JAK2 kinase inhibitors have entered the clinic with two now on the market, Ruxolitinib and Tofacitinib. Recently the macrocycle Pacritinib (SB1518), discovered in Singapore by S*BIO, successfully completed Phase 3 studies in myelofibrosis with an NDA filed this year (licensed to CTI Biopharma). S*BIO also developed the pan-HDAC inhibitor Pracinostat (SB939), currently in Phase 2 clinical trials. S*BIO showed that extension of JAK therapy through combination of Pacritinib and Pracinostat has a synergistic effect in JAK2-driven malignancies in vivo. Furthermore, combinations of JAK and HDAC inhibitors are now being studied in the clinic. Given the challenges of developing combination therapies and treating resistant cancers we have further developed Pacritnib and Ruxolitinib by merging them in a designed multiple ligand (DML) strategy with an HDAC pharmacophore. Following optimisation we have shown that these single molecules inhibit both JAK2 and HDACs, with distinct selectivity profiles, displaying dual activity in cells. This presentation will show it is possible for medicinal chemists to ‘tune’ small molecules with multiple pharmacologies for potential application in poorly treated resistant diseases.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectNanotechnology
  • BylineArticles whose byline prints “Brian W Dymock”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels